

SPINE SAFETY WARNING:

**Information for Healthcare Professionals:  
Important Revisions to the Prescribing Information for  
Lodine® (etodolac capsules and tablets)**

According to MedWatch, modifications have been made to the CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS sections of Lodine® (etodolac capsules and tablets) labeling. The revised CONTRAINDICATIONS section advises that Lodine® is contraindicated in patients with known hypersensitivity to etodolac or other ingredients in Lodine®. The revised WARNINGS section addresses renal effects and indicates that caution is recommended in patients with pre-existing kidney disease.

The complete MedWatch Safety Labeling Changes, including Wyeth Pharmaceuticals' contact information for additional prescribing information, are available at:

<http://www.fda.gov/medwatch/SAFETY/2007/oct07.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS Web site at

<http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.